A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)

A Comparative Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of V110 Formulated With Either All New Process Polysaccharides or All Current Process Polysaccharides

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00127153

Enrollment

130

Registered

2005-08-05

Start date

2005-03-31

Completion date

2005-05-31

Last updated

2015-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Pneumococcal Infections

Brief summary

The purpose of this trial is to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adults.

Interventions

BIOLOGICALV110, pneumococcal vaccine polyvalent

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Males and females in good health, ages 20-40, with no history of pneumococcal vaccination

Exclusion criteria

* Subjects with a recent febrile illness * Known or suspected immune dysfunction, conditions associated with immunosuppression, and receipt of immunosuppressive chemotherapy, including long-term corticosteroid therapy

Design outcomes

Primary

Measure	Time frame
Immunogenicity	—

Secondary

Measure	Time frame
Safety	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026